Chiasma, Inc. (CHMA): Price and Financial Metrics


Chiasma, Inc. (CHMA)

Today's Latest Price: $3.99 USD

0.06 (1.53%)

Updated Nov 24 4:00pm

Add CHMA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CHMA Stock Price Chart Interactive Chart >

Price chart for CHMA

CHMA Price/Volume Stats

Current price $3.99 52-week high $7.75
Prev. close $3.93 52-week low $2.88
Day low $3.90 Volume 1,103,400
Day high $4.01 Avg. volume 542,475
50-day MA $4.14 Dividend yield N/A
200-day MA $4.74 Market Cap 230.64M

Chiasma, Inc. (CHMA) Company Bio


Chiasma Inc. focuses on developing and commercializing oral forms of therapies for patients suffering from orphan diseases. The company was founded in 2001 and is based in Newton, Massachusetts.


CHMA Latest News Stream


Event/Time News Detail
Loading, please wait...

CHMA Latest Social Stream


Loading social stream, please wait...

View Full CHMA Social Stream

Latest CHMA News From Around the Web

Below are the latest news stories about Chiasma Inc that investors may wish to consider to help them evaluate CHMA as an investment opportunity.

Chiasma finance chief to depart

Chiasma (CHMA) reports that President and Principal Financial Officer Mark Fitzpatrick intends to step down. He will remain on the job until no later than June 30, 2021 to ensure a smooth transition to his successor. A search is underway....

Seeking Alpha | October 1, 2020

Crinetics Pharmaceuticals- Superior Molecules In Endocrinology

Crinetics Pharmaceuticals (CRNX) has a lead molecule, paltusotine, that may be best in class. Phase 2 testing is on track to be completed in Q4 2020 and may act as a catalyst for the stock to move up if the data is positive. Peak sales potential for paltusotine, if approved,...

Sage Advisors on Seeking Alpha | September 1, 2020

Were Hedge Funds Right About Chiasma Inc (CHMA)?

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]

Yahoo | July 9, 2020

Camargo client Chiasma receives FDA approval for first and only oral somatostatin analog for long-term maintenance treatment of acromegaly

CINCINNATI , July 2, 2020 /PRNewswire/ -- Camargo Pharmaceutical Services, LLC, congratulates Chiasma, Inc. on obtaining approval from the US Food and Drug Administration for MYCAPSSA® (octreotide) capsules. MYCAPSSA is the first and only oral somatostatin analog (SSA) approved by the FDA. … Full story available on Benzinga.com

Benzinga Feeds | July 2, 2020

Why Chiasma’s Shares Are Down Today

On Wednesday morning, Chiasma, Inc. (NASDAQ: CHMA) announced the pricing of a public offering of common stock and pre-funded warrants. Naturally, investors are not thrilled about the company's decision to dilute its existing shareholders, which explains why Chiasma's shares are plunging today. Chiasma first announced its intention to initiate a public offering of common stock and pre-funded warrants after the market closed on Tuesday.

Yahoo | July 1, 2020

Read More 'CHMA' Stories Here

CHMA Price Returns

1-mo 4.18%
3-mo -19.56%
6-mo -36.16%
1-year -25.00%
3-year 99.50%
5-year -81.48%
YTD -19.56%
2019 59.49%
2018 82.94%
2017 -12.82%
2016 -90.04%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7484 seconds.